Veozah vs Hormone Therapy: New Research on Hot Flash Treatments

For decades, women experiencing the intense heat and disruption of menopausal hot flashes have faced a limited menu of highly effective medical treatments.

Up to 80% of women transition through menopause experiencing vasomotor symptoms, including hot flashes and night sweats, which can severely impact sleep quality, daily productivity, and overall quality of life. While traditional systemic hormone therapy remains the gold standard for many, a significant percentage of women cannot or prefer not to use hormones due to personal medical histories, such as a history of estrogen-receptor-positive breast cancer, blood clots, or individual preferences regarding hormone use. Until recently, non-hormonal alternatives like certain antidepressants or nerve pain medications offered only modest relief, leaving a critical gap in care for women experiencing moderate to severe symptoms.

The landscape of menopause management shifted dramatically with the FDA approval of Veozah (fezolinetant), a first-in-class non-hormonal medication specifically designed to target the brain's temperature control center. This comprehensive guide explores the clinical differences between Veozah vs hormone therapy, detailing how this new medication works, examining the latest research on efficacy and safety, and helping patients understand how to discuss these evolving treatment options with a board-certified physician.

Understanding Vasomotor Symptoms and the Need for New Options

Vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, are the hallmark clinical signs of the menopausal transition. These episodes are characterized by a sudden, intense feeling of heat primarily in the upper body, often accompanied by flushing of the skin, heavy sweating, a rapid heartbeat, and subsequent chills. The physiological mechanism behind VMS has long been linked to fluctuating and declining estrogen levels, which cause the hypothalamus—the brain's internal thermostat—to become highly sensitive to slight changes in body temperature. When the brain falsely perceives the body as being too hot, it triggers a cascade of cooling mechanisms, resulting in the classic hot flash.

For many years, the primary and most effective medical intervention was replacing the lost estrogen through hormone therapy. However, the need for alternative treatments has grown substantially. Medical history plays a pivotal role; individuals with a history of certain cardiovascular diseases, unexplained vaginal bleeding, stroke, deep vein thrombosis, or hormone-sensitive cancers are generally advised against traditional hormone therapy. Furthermore, the findings of the Women's Health Initiative in the early 2000s, though now understood with much more nuance by medical professionals, created a lingering hesitancy among the general public regarding systemic hormone use.

This gap in acceptable and highly effective treatment modalities left many women suffering in silence or relying on off-label uses of selective serotonin reuptake inhibitors (SSRIs) or gabapentin, which often provided only partial relief and carried their own distinct side effect profiles. The demand for a targeted, non-hormonal therapy that directly addresses the neurological root of hot flashes without affecting estrogen receptors throughout the body has driven over a decade of dedicated pharmacological research, culminating in new therapeutic avenues.

• Vasomotor symptoms affect up to 80% of menopausal women.
• Symptoms occur due to an estrogen-related narrowing of the thermoneutral zone in the hypothalamus.
• Historical non-hormonal treatments (SSRIs, gabapentin) are used off-label and vary in efficacy.
• A large demographic of women require non-hormonal options due to medical contraindications or personal preference.

The Impact on Quality of Life

The impact of severe hot flashes extends far beyond temporary physical discomfort. Chronic night sweats lead to fragmented sleep, which in turn causes daytime fatigue, irritability, cognitive fog, and an increased risk of developing mood disorders such as anxiety and depression. Addressing these symptoms effectively is a crucial component of midlife healthcare, highlighting the importance of having multiple targeted treatment pathways available.

What is Veozah (Fezolinetant) and How Does It Work?

Veozah, known generically as fezolinetant, represents a paradigm shift in the treatment of menopausal vasomotor symptoms. Approved by the FDA in May 2023, it is the first neurokinin 3 (NK3) receptor antagonist specifically indicated for the treatment of moderate to severe hot flashes caused by menopause. Unlike traditional treatments that either replace estrogen or alter systemic neurotransmitter levels, Veozah targets the precise neural pathway responsible for temperature regulation dysfunction during menopause.

To understand how Veozah works, it is helpful to look at the brain's thermoregulatory center. In the hypothalamus, specialized neurons called KNDy (kisspeptin, neurokinin B, and dynorphin) neurons play a crucial role in regulating body temperature. These neurons are normally inhibited by estrogen. As estrogen levels precipitously drop during perimenopause and menopause, this inhibitory effect is lost. Consequently, the KNDy neurons become overactive and release excessive amounts of neurokinin B (NKB). This NKB binds to NK3 receptors, sending false signals to the brain that the body is overheating, which triggers a massive, inappropriate heat-dissipation response—the hot flash.

Veozah functions by blocking the NK3 receptor. By occupying this receptor site, the medication prevents the excess neurokinin B from binding and sending those false signals. It essentially acts as a circuit breaker, restoring balance to the brain's thermostat without introducing hormones into the bloodstream. This targeted mechanism of action allows for the mitigation of hot flashes at their neurological source, offering a scientifically elegant solution for women seeking non-hormonal relief.

• Veozah (fezolinetant) is an FDA-approved prescription medication for moderate to severe vasomotor symptoms.
• It belongs to a new class of drugs called neurokinin 3 (NK3) receptor antagonists.
• The medication works directly in the hypothalamus to block the chemical signals that trigger hot flashes.
• It does not contain estrogen or any other hormones, making it suitable for patients needing non-hormonal care.

Clinical Trial Efficacy

The FDA approval of Veozah was based on the rigorous SKYLIGHT clinical trial programs. These double-blind, placebo-controlled studies demonstrated that women taking Veozah experienced a statistically significant reduction in both the frequency and severity of hot flashes compared to those taking a placebo. Notably, many participants reported noticeable improvements within the first week of treatment, showcasing a rapid onset of action that is highly desirable for those suffering from severe daily symptoms.

Traditional Hormone Therapy (HT): The Historical Gold Standard

To accurately evaluate the comparison of Veozah vs hormone therapy, it is essential to understand the role and efficacy of traditional hormone treatments. Hormone Therapy (HT), which may include estrogen alone or a combination of estrogen and a progestogen, has been utilized for decades and remains the most comprehensively studied and statistically effective treatment for menopausal vasomotor symptoms and genitourinary syndrome of menopause (GSM).

Systemic hormone therapy works by directly replenishing the declining estrogen levels in the body. By restoring systemic estrogen, HT re-establishes the inhibitory feedback loop on the KNDy neurons in the hypothalamus, thereby stabilizing the body's thermoregulatory center. Beyond hot flashes, systemic HT offers a broad spectrum of secondary benefits. Research consistently shows that estrogen therapy helps preserve bone mineral density, reducing the risk of osteoporotic fractures later in life. It also systemically addresses vaginal dryness, joint pain, and certain mood fluctuations associated with the menopausal transition.

However, hormone therapy is not universally appropriate. The decision to initiate HT requires a thorough medical evaluation. Current medical guidelines suggest that HT is safest and most effective when initiated in women who are under the age of 60 or within 10 years of menopause onset. Risks associated with HT can include an increased likelihood of blood clots, stroke, and, depending on the formulation and duration of use, a slight increase in breast cancer risk. Therefore, healthcare providers must carefully weigh the significant benefits against an individual's personal and familial risk factors.

• Hormone Therapy addresses the root cause of menopause symptoms by replacing lost estrogen.
• It remains the most effective available treatment for reducing hot flash frequency and severity.
• HT provides additional benefits, including bone density preservation and relief from vaginal atrophy.
• Risks include potential cardiovascular issues and hormone-sensitive cancer risks in specific populations.

Forms of Administration

Hormone therapy is highly customizable. It can be administered orally via pills, or transdermally through patches, gels, and sprays. Transdermal estrogen bypasses first-pass liver metabolism, which research suggests may carry a lower risk of venous thromboembolism (blood clots) compared to oral estrogen. Women with an intact uterus must take a progestogen alongside estrogen to protect the uterine lining from hyperplasia.

Veozah vs Hormone Therapy: A Comprehensive Comparison

When comparing Veozah vs hormone therapy, patients and physicians must evaluate several distinct clinical parameters: mechanism of action, overall efficacy, symptom coverage, side effect profiles, and contraindications. Understanding these differences is vital for informed decision-making in menopausal healthcare.

In terms of efficacy for hot flashes, traditional systemic hormone therapy is generally considered to yield the highest percentage reduction in symptom frequency and severity—often reducing symptoms by 75% to 90%. Veozah, while highly effective, demonstrated a slightly lower total percentage reduction in clinical trials, though the relief is still statistically and clinically significant, often reducing symptoms by over 60%. However, Veozah holds a distinct advantage in its targeted nature; it exclusively addresses vasomotor symptoms without the systemic tissue effects of estrogen.

Symptom coverage is another major point of divergence. Hormone therapy is a broad-spectrum treatment. It alleviates hot flashes, prevents bone loss, treats vaginal dryness, and may improve skin elasticity and joint aches. Veozah is a narrow-spectrum treatment. It is specifically approved and effective solely for vasomotor symptoms. Women taking Veozah for hot flashes who also experience vaginal dryness or bone density concerns will need separate, additional treatments for those specific issues.

Safety profiles and required monitoring also differ significantly. Hormone therapy carries contraindications related to cardiovascular disease, liver disease, and hormone-sensitive cancers. Veozah's primary safety concern revolves around liver function. In clinical trials, a small percentage of women experienced elevated liver enzymes. Therefore, the FDA requires patients to undergo liver blood tests before starting Veozah, and routinely every three months for the first nine months of use. Veozah is contraindicated in individuals with known cirrhosis, severe renal impairment, or end-stage renal disease.

• Efficacy: HT provides the highest overall reduction in VMS; Veozah provides highly significant, though slightly lower, reduction rates.
• Scope: HT treats hot flashes, bone loss, and vaginal symptoms; Veozah treats only hot flashes.
• Monitoring: Veozah requires baseline and routine liver enzyme testing; HT requires routine breast and pelvic exams.
• Systemic Effects: HT affects tissues body-wide; Veozah works specifically on neurokinin receptors in the brain.

Drug Interactions

Veozah is metabolized by the CYP1A2 enzyme in the liver. It cannot be taken concurrently with medications that are strong CYP1A2 inhibitors, as this can increase the levels of Veozah in the blood. Patients must provide a comprehensive list of all medications, supplements, and vitamins to their healthcare provider when exploring this option.

Who is the Ideal Candidate for Non-Hormonal Treatments?

Determining the right approach to managing menopausal symptoms is a highly individualized process. The emergence of NK3 receptor antagonists has vastly improved the landscape for specific demographics of women who previously had limited, sub-optimal choices.

The most straightforward candidates for Veozah are women with absolute contraindications to hormone therapy. This includes breast cancer survivors, individuals currently undergoing treatment for hormone-receptor-positive cancers, women with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE), and those with a history of stroke or transient ischemic attacks (TIAs). For these patients, Veozah represents a monumental medical advancement, offering a mechanism to control severe, quality-of-life-altering hot flashes without introducing systemic oncological or thrombotic risks.

Additionally, Veozah is an excellent option for women who simply prefer not to use hormones. Despite the established safety profile of modern hormone therapy for appropriate candidates, personal medical philosophy and comfort levels vary. Women who seek a targeted neurological approach rather than systemic endocrine replacement may find Veozah aligns better with their healthcare goals. Furthermore, patients who have tried hormone therapy but experienced intolerable side effects—such as breast tenderness, unexpected spotting, or mood changes—may transition to a non-hormonal alternative like Veozah to manage their vasomotor symptoms.

It is highly recommended that women learn more about their comprehensive healthcare options by reading resources on the health blog or reviewing the services offered regarding menopause management. A thorough consultation with a board-certified internal medicine physician is essential to evaluate individual cardiovascular risk, bone health, and liver function before committing to a specific treatment pathway.

• Ideal candidates include women with a history of estrogen-sensitive cancers.
• Women with a history of blood clots, heart attacks, or stroke are excellent candidates for non-hormonal care.
• Patients who experience adverse side effects from systemic estrogen can benefit from switching to NK3 antagonists.
• Personal preference for avoiding hormone replacement is a valid and common reason to pursue Veozah.

Navigating the Decision Process

The decision-making process should involve a detailed review of a patient's medical history, current symptom burden, and long-term health goals. Physicians at Kelsey-Seybold Clinic carefully map out the risk-to-benefit ratio for each patient. By understanding the distinct mechanisms of Veozah vs hormone therapy, women are empowered to advocate for the treatment plan that best suits their unique physiological needs.

Conclusion

The approval of Veozah represents one of the most significant advancements in women's midlife health in decades, providing a targeted, highly effective non-hormonal option for moderate to severe hot flashes. While traditional hormone therapy remains a comprehensive gold standard for treating a wide array of menopausal symptoms, Veozah bridges a critical gap for women who cannot or choose not to use systemic estrogen. Understanding the nuances of Veozah vs hormone therapy allows patients to approach their midlife transition with confidence, knowing there are multiple scientifically backed pathways to relief.

Menopause is a natural transition, but enduring debilitating symptoms is not a requirement. Every woman deserves access to personalized, evidence-based care that honors her medical history and personal preferences.

To explore which hot flash treatment is right for you, schedule an appointment to speak with a board-certified physician today. Learn more about Dr. V's background in women's health by visiting the about page. Medical decisions should always be made in partnership with a healthcare provider.

*Disclaimer: Women's health decisions should be made in partnership with your healthcare provider. This content is for educational purposes and does not replace professional medical advice. Individual results vary, and this information is not a substitute for professional medical evaluation.*

Frequently Asked Questions

Can I switch from hormone therapy to Veozah?

Yes, it is possible to transition from hormone therapy to Veozah, particularly if a patient develops a contraindication to hormones or wishes to stop them. However, this transition must be guided by a physician to safely taper hormones and monitor for any returning symptoms.

Does Veozah help with menopause symptoms other than hot flashes?

No. Veozah is specifically approved to treat moderate to severe vasomotor symptoms (hot flashes and night sweats). It does not treat other symptoms of menopause, such as vaginal dryness, bone density loss, or mood changes.

How quickly does Veozah start working?

In clinical trials, many women reported a noticeable reduction in the frequency and severity of hot flashes within the first one to two weeks of starting Veozah, though individual results can vary.

Are there any specific tests needed before starting Veozah?

Yes. Because Veozah can cause elevated liver enzymes in a small percentage of users, the FDA requires baseline blood tests to check liver function before starting the medication, followed by routine testing every three months for the first nine months.

Is Veozah safe for breast cancer survivors?

Veozah is non-hormonal and does not contain estrogen, making it an important option for breast cancer survivors who suffer from severe hot flashes. Patients should always consult their oncologist and primary care physician to ensure it is appropriate for their specific medical profile.

---

Women's health decisions should be made in partnership with your healthcare provider. This content is for educational purposes and does not replace professional medical advice.